Accessibility StatementSkip Navigation On this news, Savara's stock price fell $0.90 per share, or 31.69%, to close at $1.94 per share on May 27, 2025. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Savara To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Savara between March 7, 2024 and May 23, 2025and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wil ...

公司相关法律事件 - Gross Law Firm向Savara Inc (NASDAQ: SVRA)股东发布集体诉讼通知 涉及2024年3月4日至2025年5月23日期间购入股票的投资者[1][3] - 指控内容包括公司对MOLBREEVI BLA的化学制造与控制信息披露不足 FDA不太可能以当前形式批准该药物治疗肺泡蛋白沉积症的申请[3] - 公司被指需额外融资 因MOLBREEVI监管批准延迟可能影响资金状况 此前公开声明被指控存在重大虚假和误导性内容[3] 诉讼程序安排 - 股东参与截止日期为2025年11月7日 需通过指定链接完成登记[4] - 登记股东将接入案件生命周期监控系统 原告代表申请同步截止[4] - 律所提供免费参与通道 不要求必须成为原告代表即可获得赔偿资格[1][4]

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming November 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Savara Inc. ("Savara†or the "Company†) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the "Class Period†). IF YOU SUFFERED A LOSS ON YOUR SAVARA INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR. ...

NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024 and May 23, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 7, 2025. SO WHAT: If you purchased Savara securities during the Class Period y ...

Accessibility StatementSkip Navigation SAN DIEGO, Sept. 16, 2025 /PRNewswire/ -- Robbins LLPÂ reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Savara Inc. (NASAQ: SVRA) securities between March 7, 2024 and May 23, 2025. Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. The Company's lead product candidate is MOLBREEVI (also referred to as "molgramostim"), an inhaled granulocyte-macrophage colony ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Why:Â Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024 and May 23, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 7, 2025. So what: If you purchased Savara s ...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that an investor filed a class action lawsuit on behalf of purchasers of securities of Savara Inc. (NASDAQ: SVRA), between March 7, 2024 and May 23, 2025, both dates inclusive (the "Class Period†). Savara is a clinical- stage biopharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allega. ...

诉讼核心信息 - Levi & Korsinsky律所通知Savara Inc投资者可参与集体诉讼[1] - 诉讼旨在为在2024年3月4日至2025年5月23日期间因涉嫌证券欺诈而遭受损失的投资者挽回损失[1] - 投资者需在2025年11月7日前请求法院任命其为首席原告[3] 指控内容 - 指控称被告做出虚假陈述和/或隐瞒了关键药物MOLBREEVI的生物制剂许可申请缺乏足够的化学、制造和控制信息[2] - 因此美国FDA不太可能以当前形式批准MOLBREEVI的BLA[2] - 上述情况使得公司不太可能在其向投资者承诺的时间框架内完成MOLBREEVI的BLA提交[2] - MOLBREEVI监管批准的延迟增加了公司需要筹集额外资金的可能性[2] - 被告的公开陈述在所有相关时间点均存在重大虚假和误导性[2]

事件概述 - 律师事务所Kirby McInerney LLP提醒在特定期间内购买Savara Inc公司证券的投资者，可联系该所以讨论其在证券欺诈集体诉讼中的权利或利益 [1] - 诉讼源于美国食品药品监督管理局拒绝了公司为治疗aPap的MOLBREEVI所提交的生物制品许可申请 [3] - 受此消息影响，公司股价在2025年5月27日出现大幅下跌 [3] 监管审批事件 - 2025年5月27日，公司宣布其MOLBREEVI BLA收到了FDA的拒绝提交信件 [3] - FDA的初步审查认为，该申请在化学、制造和控制方面信息不足，未能达到进行实质性审查的完整性要求 [3] - 此事件导致Savara公司股价从2025年5月23日的每股2.84美元下跌0.90美元，至2025年5月27日收盘时的每股1.94美元，跌幅约为31.69% [3] 诉讼指控内容 - 诉讼代表在2024年3月7日至2025年5月23日期间购买公司证券的投资者提起 [4] - 指控称公司在上述期间内作出了虚假和/或误导性陈述，和/或未能披露关键信息 [4] - 具体指控包括：MOLBREEVI BLA缺乏足够的CMC信息；因此FDA不太可能批准其当前形式的申请；公司不太可能在其向投资者承诺的时间框架内完成BLA提交；监管批准的延迟增加了公司需要筹集额外资本的可能性 [4]

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming November 7, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Savara Inc. ("Savara†or the "Company†) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the "Class Period†). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SAVARA INC. (SVRA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES F. ...